185 related articles for article (PubMed ID: 12109515)
1. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.
Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515
[TBL] [Abstract][Full Text] [Related]
2. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
3. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
[TBL] [Abstract][Full Text] [Related]
4. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
5. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles.
Keller T; Bitterlich N; Hilfenhaus S; Bigl H; Löser T; Leonhardt P
J Cancer Res Clin Oncol; 1998; 124(10):565-74. PubMed ID: 9829861
[TBL] [Abstract][Full Text] [Related]
8. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
10. Decision guarantee in tumour marker analysis: a cut-off independent assessment.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(4A):1933-9. PubMed ID: 17649799
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
12. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
13. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
[TBL] [Abstract][Full Text] [Related]
14. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
15. Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels.
Schneider J
Cancer Biomark; 2010; 6(3-4):149-62. PubMed ID: 20660961
[TBL] [Abstract][Full Text] [Related]
16. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
17. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
18. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
19. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]